MétaCan
Menu
Back to cohort
Record W4385638922 · doi:10.1038/s41598-023-39301-4

New drugs and stock market: a machine learning framework for predicting pharma market reaction to clinical trial announcements

2023· article· en· W4385638922 on OpenAlexaff
Semen Budennyy, Alexey Kazakov, Elizaveta Kovtun, Leonid Zhukov

Bibliographic record

VenueScientific Reports · 2023
Typearticle
Languageen
FieldComputer Science
TopicExplainable Artificial Intelligence (XAI)
Canadian institutionsArtificial Intelligence in Medicine (Canada)
Fundersnot available
KeywordsEvent studyPortfolioComputer scienceStock marketArtificial intelligenceMachine learningMarket capitalizationEconometricsBusinessActuarial scienceEconomicsFinance

Abstract

fetched live from OpenAlex

Pharmaceutical companies operate in a strictly regulated and highly risky environment in which a single slip can lead to serious financial implications. Accordingly, the announcements of clinical trial results tend to determine the future course of events, hence being closely monitored by the public. Most works focus on retrospective analysis of announcement impact on company stock prices, bypassing the consideration of the problem in the predictive paradigm. In this work, we aim to close this gap by proposing a framework that allows predicting the numerical values of announcement-induced changes in stock prices. In fact, it is a problem of the impact prediction of the specific event on the corresponding time series. Our framework includes a BERT model for extracting the sentiment polarity of announcements, a Temporal Fusion Transformer for forecasting the expected return, a graph convolution network for capturing event relationships, and gradient boosting for predicting the price change. We operate with one of the biggest FDA (the Food and Drug Administration) datasets, consisting of 5436 clinical trial announcements from 681 companies for the years 2018-2022. During the study, we get several significant outcomes and domain-specific insights. Firstly, we obtain statistical evidence for the clinical result promulgation influence on the public pharma market value. Secondly, we witness inherently different patterns of responses to positive and negative announcements, reflected in a stronger and more pronounced reaction to negative clinical news. Thirdly, we discover two factors that play a crucial role in a predictive framework: (1) the drug portfolio size of the company, indicating the greater susceptibility to an announcement in the case of low diversification among drug products and (2) the announcement network effect, manifesting through an increase in predictive power when exploiting interdependencies of events belonging to the same company or nosology. Finally, we prove the viability of the forecast setting by getting ROC AUC scores predominantly greater than 0.7 for the classification of price change on historical data. We emphasize the transferability and generalizability of the developed framework on other datasets and domains but on the condition of the presence of two key entities: events and the associated time series.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: Simulation or modeling
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.009
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.074
GPT teacher head0.382
Teacher spread0.308 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueScientific ReportsSame topicExplainable Artificial Intelligence (XAI)French-language works237,207